Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Saeid Mohseni, Ali Tavakoli, Hamid Ghazipoor, Neda Pouralimohamadi, Roghayeh Zare, Thomas Rampp, Maryam Shayesteh, Mehdi Pasalar
{"title":"Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.","authors":"Saeid Mohseni, Ali Tavakoli, Hamid Ghazipoor, Neda Pouralimohamadi, Roghayeh Zare, Thomas Rampp, Maryam Shayesteh, Mehdi Pasalar","doi":"10.3389/fnut.2025.1494351","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.</p><p><strong>Methods: </strong>To identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.</p><p><strong>Results: </strong>In this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.</p><p><strong>Conclusion: </strong>The findings highlight curcumin's potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin's efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024567247.</p>","PeriodicalId":12473,"journal":{"name":"Frontiers in Nutrition","volume":"12 ","pages":"1494351"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Nutrition","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fnut.2025.1494351","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Inflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.
Methods: To identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.
Results: In this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.
Conclusion: The findings highlight curcumin's potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin's efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.
炎症性肠病（IBD），包括克罗恩病（CD）和溃疡性结肠炎（UC），由于免疫反应失调和遗传易感性，在管理方面提出了复杂的挑战。本研究探讨了姜黄素作为IBD辅助治疗的潜力，通过对临床试验的系统回顾来评估其有效性和安全性，以提高治疗策略和结果。方法：为确定姜黄素治疗IBD的安慰剂对照随机临床试验，检索Medline/PubMed、Scopus、Embase、Web of Knowledge、谷歌Scholar等数据库，检索时间截止到2024年5月。纳入标准侧重于比较IBD患者姜黄素与安慰剂的随机对照试验，使用既定的方法和工具进行数据提取和分析，以全面综合和评估研究结果。结果：在这项荟萃分析中，筛选了362份记录并进行了全文综述，纳入了13项关于姜黄素治疗IBD的安慰剂对照rct。大多数试验集中于UC患者，并于2010年后发表，使用不同剂量和持续时间的口服姜黄素。分析显示，姜黄素在UC患者实现临床缓解和反应方面具有显著疗效，并观察到异质性。姜黄素组和安慰剂组的不良事件和戒断率没有显著差异。在乳糜泻患者中，姜黄素在临床和内窥镜缓解方面没有表现出优于安慰剂的优势。结论：研究结果强调了姜黄素治疗UC的潜力，但对CD的疗效尚无定论，强调需要进一步研究。姜黄素治疗IBD的多重机制包括抗炎、抗氧化、微生物群调节和免疫调节特性。有必要进一步研究以提高认识和治疗效果。系统评审注册：https://www.crd.york.ac.uk/PROSPERO/view/CRD42024567247。
期刊介绍：
No subject pertains more to human life than nutrition. The aim of Frontiers in Nutrition is to integrate major scientific disciplines in this vast field in order to address the most relevant and pertinent questions and developments. Our ambition is to create an integrated podium based on original research, clinical trials, and contemporary reviews to build a reputable knowledge forum in the domains of human health, dietary behaviors, agronomy & 21st century food science. Through the recognized open-access Frontiers platform we welcome manuscripts to our dedicated sections relating to different areas in the field of nutrition with a focus on human health.
Specialty sections in Frontiers in Nutrition include, for example, Clinical Nutrition, Nutrition & Sustainable Diets, Nutrition and Food Science Technology, Nutrition Methodology, Sport & Exercise Nutrition, Food Chemistry, and Nutritional Immunology. Based on the publication of rigorous scientific research, we thrive to achieve a visible impact on the global nutrition agenda addressing the grand challenges of our time, including obesity, malnutrition, hunger, food waste, sustainability and consumer health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
